cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Omeros Corporation
11 own
25 watching
Current Price
$4.04
$-0.02
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
204.94M
52-Week High
52-Week High
6.36000
52-Week Low
52-Week Low
0.92000
Average Volume
Average Volume
0.28M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization204.94M
icon52-Week High6.36000
icon52-Week Low0.92000
iconAverage Volume0.28M
iconDividend Yield--
iconP/E Ratio--
What does the Omeros Corporation do?
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The company's preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Read More
How much money does Omeros Corporation make?
News & Events about Omeros Corporation.
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the late-breaker session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros website. The presentation, which details data from a pre-specified interim...
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the companys lead MASP-3 inhibitor, in complement-inhibitor-nave adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and...
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the...
Business Wire
1 year ago
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at...
Business Wire
1 year ago
Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (Rayner) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the Agreement), pursuant to which Omeros sold its ophthalmology product OMIDRIA to Rayner in...
Frequently Asked Questions
Frequently Asked Questions
What is Omeros Corporation share price today?
plus_minus_icon
Can Indians buy Omeros Corporation shares?
plus_minus_icon
How can I buy Omeros Corporation shares from India?
plus_minus_icon
Can Fractional shares of Omeros Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Omeros Corporation stocks?
plus_minus_icon
What is today’s traded volume of Omeros Corporation?
plus_minus_icon
What is today’s market capitalisation of Omeros Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Omeros Corporation?
plus_minus_icon
What percentage is Omeros Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Omeros Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$4.04
$-0.02
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00